Bristol-Myers Squibb Company’s Stock Price Soars to $63.11, Marking a Remarkable 3.31% Increase

Bristol-Myers Squibb Company (BMY)

63.11 USD +2.02 (+3.31%) Volume: 20.26M

Bristol-Myers Squibb Company’s stock price is currently at 63.11 USD, marking a positive trading session with a +3.31% increase and a high trading volume of 20.26M. With a year-to-date percentage change of +11.58%, BMY’s stock performance continues to show promising growth.

Latest developments on Bristol-Myers Squibb Company

Recent events have propelled Bristol-Myers Squibb’s stock price movements today. The company’s trial results for Sotyktu in psoriatic arthritis have been met with success, with over 50% of participants responding positively. Additionally, Bristol Myers’ immunotherapy combination of Opdivo and Yervoy has received approval from the EC for advanced liver cancer treatment. These developments have led to bullish call volume and a 9.2% stock gain in the past month. With positive late-stage data and potential paradigm-shifting drugs in the pipeline, Bristol-Myers Squibb remains a top choice for investors looking for dividend stocks to buy now.

A look at Bristol-Myers Squibb Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Bristol-Myers Squibb has a promising long-term outlook. With a perfect score of 5 in Dividend and Momentum, the company is showing strong performance in terms of its dividend payments and stock price momentum. This indicates stability and growth potential for investors looking for consistent returns.

While Bristol-Myers Squibb scored lower in Value, Growth, and Resilience, with scores of 2 for each, the company still shows potential for future growth and resilience in the face of challenges. With a focus on developing products and therapies for various health conditions, including cancer, heart disease, and diabetes, Bristol-Myers Squibb remains a key player in the biopharmaceutical industry with a diverse portfolio of offerings.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma